WO1998018430A3 - P2y receptor antagonists - Google Patents

P2y receptor antagonists Download PDF

Info

Publication number
WO1998018430A3
WO1998018430A3 PCT/US1997/019922 US9719922W WO9818430A3 WO 1998018430 A3 WO1998018430 A3 WO 1998018430A3 US 9719922 W US9719922 W US 9719922W WO 9818430 A3 WO9818430 A3 WO 9818430A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
receptor
antagonists
utp
atp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/019922
Other languages
French (fr)
Other versions
WO1998018430A2 (en
Inventor
Jose L Boyer
T Kendall Harden
Kenneth A Jacobson
Emidio Camaioni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Priority to EP97952172A priority Critical patent/EP0929218A4/en
Priority to AU55846/98A priority patent/AU5584698A/en
Priority to JP52080798A priority patent/JP2001504097A/en
Publication of WO1998018430A2 publication Critical patent/WO1998018430A2/en
Publication of WO1998018430A3 publication Critical patent/WO1998018430A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel P2Y receptor antagonists derived from ATP and UTP are described. P2Y receptor antagonists with competitive antagonist activity at the P2Y receptor are described in particular, as are P2Y receptor antagonists that bind selectively to the P2Y1 receptor. Also described herein are methods of detecting a P2Y receptor in a biological sample.
PCT/US1997/019922 1996-10-30 1997-10-23 P2y receptor antagonists Ceased WO1998018430A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97952172A EP0929218A4 (en) 1996-10-30 1997-10-23 R2Y RECEPTOR ANTAGONISTS
AU55846/98A AU5584698A (en) 1996-10-30 1997-10-23 P2y receptor antagonists
JP52080798A JP2001504097A (en) 1996-10-30 1997-10-23 P2Y receptor antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2985596P 1996-10-30 1996-10-30
US60/029,855 1996-10-30

Publications (2)

Publication Number Publication Date
WO1998018430A2 WO1998018430A2 (en) 1998-05-07
WO1998018430A3 true WO1998018430A3 (en) 1998-06-18

Family

ID=21851254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019922 Ceased WO1998018430A2 (en) 1996-10-30 1997-10-23 P2y receptor antagonists

Country Status (5)

Country Link
EP (1) EP0929218A4 (en)
JP (1) JP2001504097A (en)
AU (1) AU5584698A (en)
CA (1) CA2241687A1 (en)
WO (1) WO1998018430A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100719606B1 (en) 1998-02-25 2007-05-17 에모리 유니버시티 2'-fluoronucleosides
SE9802574D0 (en) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US20040122223A1 (en) * 2001-02-07 2004-06-24 Davis Jeremy Martin Non-natural nucleotides and dinucleotides
KR20050043761A (en) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 Method for treating or preventing inflammatory diseases
KR20050097971A (en) * 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Partial and full agonists of a1 adenosine receptors
ATE460402T1 (en) 2004-05-12 2010-03-15 Bristol Myers Squibb Co UREA ANTAGONISTS OF THE P2Y1 RECEPTOR SUITABLE FOR THE TREATMENT OF THROMBOTIC DISEASES
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1954696B1 (en) 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
AR056867A1 (en) * 2005-06-27 2007-10-31 Bristol Myers Squibb Co HETEROCICLIC ANTAGONISTS N- LINKED TO THE RECEIVER OF P2Y1 USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS. PHARMACEUTICAL COMPOSITIONS.
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (en) 2005-06-27 2011-05-05 Bristol Myers Squibb Co LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
AR064245A1 (en) 2006-11-17 2009-03-25 Epix Delaware Inc ADENOSINE ANALOGS AND ITS USE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122529A1 (en) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphate analogs of the nucleoside di and tnphosphate and processes for their preparation
JPS4911896A (en) * 1972-05-15 1974-02-01
DE2331223C2 (en) * 1972-06-19 1984-11-22 Kohjin Co., Ltd., Tokio / Tokyo S-substituted-2-thioadenosines, their 5'-monophosphates, processes for their preparation and pharmaceuticals containing them
US4266048A (en) * 1977-10-11 1981-05-05 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of analogs of 3'-phosphoadenosine 5'-phosphosulfate (PAPS)
US4828979A (en) * 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
EP0508687B1 (en) * 1991-04-06 1995-09-13 Astra Pharmaceuticals Limited ATP analogues
SK281309B6 (en) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-ALKYL-2-SUBSTITUATED ADENOSIN-TRIFOSPHATE DERIVATIVES, METHODS OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE OF THESE DERIVATIVES
WO1995010287A1 (en) * 1993-10-15 1995-04-20 Wisconsin Alumni Research Foundation Substituted purine nucleoside analogs and method for treating endotoxin shock
US5712258A (en) * 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BR. J. PHARMACOL., 1996, Vol. 118, No. 8, BOYER J.L. et al., "Identification of Potent P2Y-Purinoceptor Agonists that are Derivatives of Adenosine 5'-Monophosphate", pages 1959-1964. *
CHEMICAL ABSTRACTS, Abstract No. 126:43223, FAN J. et al., "DNA Sequencing with (.alpha.33-P)-Labelled ddNTP Terminators: A New Approach to DNA Sequencing with Thermo Sequenase DNA Polymerase"; & BIOTECHNIQUES, 1996, Vol. 21, No. 6, pages 1132-1137. *
DRUG DESIGN AND DISCOVERY, 1995, Vol. 13, VANRHEE et al., "Modelling the P2Y Purinoceptor Using Rhodopsin as Template", pages 133-154. *
PHARMACOLOGY TOXICOLOGY, 1995, Vol. 76, SIMON J. et al., "Characterization of P2Y Purinoceptor in Brain", pages 302-307. *
See also references of EP0929218A4 *

Also Published As

Publication number Publication date
EP0929218A4 (en) 2001-05-16
EP0929218A2 (en) 1999-07-21
WO1998018430A2 (en) 1998-05-07
JP2001504097A (en) 2001-03-27
CA2241687A1 (en) 1998-05-07
AU5584698A (en) 1998-05-22

Similar Documents

Publication Publication Date Title
WO1998018430A3 (en) P2y receptor antagonists
CA2078572A1 (en) Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
IS5860A (en) 4,4-barylpiperidine derivatives with opioid receptor activity
NO994972D0 (en) Polymer blends with improved elongation
DZ2320A1 (en) Vitronectin receptor antagonists.
DE69628484D1 (en) Cyclic compounds, their preparation and their use as tachykinin receptor antagonists
ATE201016T1 (en) PYRIMIDINDIONE, PYRIMIDINDRION, TRIAZINDIONE DERIVATIVES AS ALPHA-1 ADRENERGIC RECEPTOR ANTAGONISTS
DK0920438T3 (en) N6 heterocyclic-substituted adenosine derivatives
NO20002800L (en) Cyclosporin-containing microemulsion, for concentrate composition
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
EP1028186A4 (en) Nonwoven fabric, and sheetlike materials and synthetic leathers made by using the same
MA23172A1 (en) ENDOTHELIN RECEPTOR ANTAGONISTS.
ES2057571T3 (en) PDGF-ALPHA RECEIVER.
NO991079L (en) Azinyloxy and phenoxy-diaryl-carboxylic acid derivatives, their preparation and their use as mixed ETA / ETB endothelin receptor antagonists
BR0007864A (en) Compound, and, use of a compound
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
NO20000279D0 (en) Broad MWD, compositionally uniform ethylene interpolymer blend, process for its preparation, and articles made therefrom
DE50008020D1 (en) SUBSTITUTED PYRROLIDIN-2,3,4-TRION DERIVATIVES EFFECTIVE AS NMDA RECEPTOR ANTAGONISTS
EP1244450A4 (en) ANTAGONISTS NMDA / NR2B 8-AZA-BICYCLO [3.2.1] OCTANE
ID26234A (en) HETEROSICLIC CARBOXICATE ACID DECREASES, PRODUCTION AND USE AS ENDOTELEN RECEPTOR ANTAGONISTS
EP0876598A4 (en) 1.2 IMPROVED CHIMILUMINESCENT DIOXETANES
FI971528A7 (en) Pyrrolyltetrahydrobenzoquinoxalinediones, their preparation and use as glutamate receptor antagonists
EP1108212A4 (en) Methods and materials for diagnosing unstable angina
ID24819A (en) HERTHICICLIC SUBSTITUTION, MAKING AND USING IT AS ENDOTELINE RECEPTOR ANTAGONISTS
FI904028A7 (en) Bar soap with improved crack resistance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR

ENP Entry into the national phase

Ref document number: 2241687

Country of ref document: CA

Ref country code: CA

Ref document number: 2241687

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 55846/98

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 520807

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997952172

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

WWP Wipo information: published in national office

Ref document number: 1997952172

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997952172

Country of ref document: EP